Saferon should be given with caution to patients with a history of allergic disorders or asthma, and in these patients the intramuscular route is to be preferred.

Patients with rheumatoid arthritis may experience a worsening of symptoms when given saferon intravenously.
Large doses of saferon by infusion may lead to serum discoloration; this should not be mistaken as evidence of haemolysis.

Oral iron salts should be stopped before giving parenteral iron. A test dose should be given before a full therapeutic dose is given and emergency measures for the treatment of allergic reactions should be available.
Patients should be kept under observation for at least 1 hour after a test dose .

Do not mix Saferon injection with other medications or add to parenteral nutrition solutions for intravenous infusion.


Saferon should not be used during the first trimester of pregnancy. It is recommended that treatment, should be confined to the second and third trimester, if treatment is clearly necessary.

 Nursing mothers

Caution should be exerised when Saferon is administered to nursing woman , traces of unmetabolized iron dextran are excreted in human milk

Pediatric use

Saferon not recommended for use in infants under 4 months of age